Advances in the treatment of chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Imatinib is a standard therapy for chronic myeloid leukemia (CML).
• Advances in tyrosine kinase inhibitors (TKIs) are changing CML treatment paradigms.
• Resistance to TKIs, particularly specific mutations, necessitates new therapeutic strategies.

Purpose of the Study:

• To review recent advancements in CML treatment for newly diagnosed patients.
• To explore strategies for therapy discontinuation in CML.
• To report on novel small molecule inhibitors targeting resistant BCR-ABL mutations, especially the T315I mutant.

Main Methods:

• Review of recent clinical trial results for second-generation TKIs.
• Analysis of current strategies and challenges in CML therapy cessation.
• Examination of emerging small molecule inhibitors for BCR-ABL mutations.

Main Results:

• Second-generation TKIs like dasatinib and nilotinib are emerging as frontline options.
• Therapy discontinuation for CML is primarily confined to clinical trials.
• New agents targeting the T315I mutation, such as ponatinib, are nearing approval.
• Accelerated or blastic phase CML remains difficult to treat, potentially due to BCR-ABL-independent resistance.

Conclusions:

• Frontline CML therapy is evolving with second-generation TKIs, requiring further observation.
• Understanding leukemic cell persistence is crucial for successful CML therapy discontinuation.
• Targeted therapies for T315I mutations offer significant progress for resistant CML.
• BCR-ABL-independent resistance mechanisms may explain challenges in advanced CML phases.